TRX E 002 1

Drug Profile

TRX E 002 1

Alternative Names: Cantrixil; TRX1; TRXE 002 1; TRXE-002

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novogen
  • Class Antineoplastics; Benzopyrans; Small molecules
  • Mechanism of Action Electron transport chain complex protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 07 Aug 2017 Novogen has patent protection for TRX E 002 1 in USA and Europe
  • 10 Mar 2017 Phase-I clinical trials in Ovarian cancer in Australia (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top